HK Stock Market Move | HENLIUS (02696) rises more than 5%, multiple solid tumor pipelines will debut at the ESMO ASIA 2025 conference.

HENLIUS (02696) rose more than 5%, up 4.7% at the time of writing, at HK$70.15, with a turnover of HK$16.35 million. In terms of news, according to HENLIUS official Weibo, ESMO ASIA 2025 will be held in Singapore from December 5th to December 7th. At the conference, HENLIUS will bring four products, including HLX43 (PD-L1 ADC), H (Suluricon), HLX11 (Patorzumab antibody biosimilar, US trade name: POHERDY) and HLX78 (Lasoxifen tablets), presenting 10 latest research data in the form of preferred paper oral presentations, small oral presentations, and posters. showcasing the company's diversified layout and cutting-edge exploration in the field of oncology treatment, validating the strength of the diverse innovation platform. Among them, the broad-spectrum anti-tumor ADC HLX43's phase II clinical data in cervical cancer will be released for the first time at the conference.